Abstract 1738P
Background
Tobacco remains the leading preventable risk factor for cancer in the world. Although the prevalence of tobacco use has a decreasing trend in most European countries, the availability of new smoking devices is causing an increase in smokers, especially among the younger population. Several studies have confirmed the relationship between this increase and indirect or covert advertising, carried out on social media and VOD platforms, through product placement, etc. This study aims to measure the impact of tobacco and new smoking devices in these digital spaces on the young Spanish population; and how this impact is related to increased consumption.
Methods
A survey has been conducted on the young Spanish population (aged between 16 to 21 years old) using a representative online panel of this population. The final sample obtained was 1730 interviews, and the data collection was conducted in December 2022. A questionnaire with an average duration of 10 minutes was administered, in which questions related to tobacco and new smoking devices use, and the recall of having seen content related to traditional tobacco and new smoking devices were collected. Descriptive and logistic regression analyses have been performed, taking the habitual consumption (last month) of tobacco and new smoking device as dependent variables.
Results
82.5% of young people remember having had some impact related to traditional tobacco, and 83% with new smoking forms. Among young people who have had this impact, there are twice as many smokers (53.1%) as among those who have not (24.5%). Having seen someone smoking cigarettes on these platforms (AOR 1.56), cigarette product placement (AOR 1.71), or recalling e-cigarette brands (AOR 1.58) are the variables that most increase the risk of regularly consuming traditional cigarettes. The same happens in the risk of habitual consumption of new devices, with the recall of having seen specific brands or logos taking special relevance (AOR 2.47).
Conclusions
There is a correlation between the recall of these types of consumption and the regular consumption of tobacco or new forms of smoking. It is necessary to continue researching this avenue of normalization of consumption and to ensure the protection of young people from the promotion of new devices.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Asociación Española Contra el Cáncer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1706P - Time to full approval of novel anticancer medicines granted accelerated approval and implications for reform of the accelerated approval pathway
Presenter: Thomas Hwang
Session: Poster session 23
1707P - Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology
Presenter: Christoph Michaeli
Session: Poster session 23
1708P - The registration pathways in China for globally developed novel anticancer drugs
Presenter: Da-wei Wu
Session: Poster session 23
1709P - Influence of censoring on conclusions of FDA-approved cancer drugs using the modified time to treatment failure
Presenter: Jonathan Ofer
Session: Poster session 23
1710P - Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
Presenter: Laurien Zeverijn
Session: Poster session 23
1711P - The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine
Presenter: Hans Gelderblom
Session: Poster session 23
1712P - Implementation of a molecular pre-screening program (MPP) in a network of public cancer centres for phase I clinical trial (Ph1-CT) candidates: The PREICO program
Presenter: Juan José Soto Castillo
Session: Poster session 23
1713P - Non-inferiority oncology clinical trials in major journals: Purposes, methods and results
Presenter: Rafael Barreto
Session: Poster session 23
1714P - Geographical disparities in access to cancer clinical trials in Korea
Presenter: Sokbom Kang
Session: Poster session 23
1715P - Analysis of the adequacy of control arms in oncology randomized clinical trials published between 2017 and 2021: A meta-research study
Presenter: Alessandro Rossi
Session: Poster session 23